Viking Therapeutics Presents New Data From Phase 1 Clinical Trial Of Dual GLP-1/GIP Receptor Agonist VK2735 In Oral Presentation At ObesityWeek 2023
Portfolio Pulse from Benzinga Newsdesk
Viking Therapeutics (NASDAQ:VKTX) has presented new data from its Phase 1 clinical trial of VK2735, a dual GLP-1/GIP receptor agonist, at ObesityWeek 2023. The data shows that 28 days of treatment with VK2735 resulted in significant reductions in liver fat content and plasma lipid levels. The treatment also resulted in weight loss of up to 7.8% from baseline. The company believes these results suggest potential benefits for patients with obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).
October 17, 2023 | 8:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Viking Therapeutics' Phase 1 trial data for VK2735 shows promising results, potentially benefiting patients with obesity, NAFLD, and NASH. This could positively impact the company's stock in the short term.
The positive results from the Phase 1 trial of VK2735 could increase investor confidence in Viking Therapeutics, potentially leading to an increase in the company's stock price. The potential benefits for patients with obesity, NAFLD, and NASH could also expand the market for VK2735, further boosting the company's prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100